ᐊᑐᓕᖅᑎᑦᑎᒃᑲᓐᓂᕐᓗᑎᒃ ᐋᓐᓂᐊᖅᑖᖅᑕᐃᓕᒍᑎᒥ RSV-ᒥ ᓄᓇᕗᒥ, ᑕᐅᓴᑲᓪᓚᖏᓐᓃᑦᑐᑦ ᐅᖃᖅᑐᑦ

“ᐃᓄᖕᓄᓪᓕ, ᑮᓇᐅᔭᓂ ᐊᑐᙱᓐᓂᕐᓴᐅᓇᔭᖅᐳᓯ ᐅᓄᖃᑦᑕᕐᓂᖏᓐᓂᒃ ᐳᕙᖏᑦᑎᒍᑦ ᐋᓐᓂᐊᖃᖃᖅᑕᖅᑐᑦ”

ᐅᓇ ᖃᖓᑕᓲᖅ ᑐᐊᕕᕐᓇᖅᑐᓕᕆᓂᕐᒧᑦ ᓄᓇᕗᑦ ᓚᐃᕝᓚᐃᓐ (Nunavut Lifeline) ᓄᖅᑲᖓᕗᖅ ᐃᖃᓗᐃᑦ ᒥᕝᕕᖓᓂ ᐊᐅᔭᖅ ᖃᖓᑕᓲᓂᒃ ᖁᙱᐊᖅᑎᑦᑎᑎᓪᓗᒋ ᖃᖓᑕᑲᑕᒃᑐᓂᒃ. ᐊᕐᕌᒍᓂ ᐃᓚᖏᓐᓂᒃ, ᓱᕈᓯᓛᑦ ᐳᕙᖏᑦᑎᒍᑦ ᐊᓪᓕᒃᑯᑦ ᐋᓐᓂᐊᖃᖅᑲᑕᓕᕌᖓᑕ (RSV, respiratory synctial virus), ᐊᐅᓪᓚᖅᑎᑕᐅᔭᕆᐊᖃᓕᖃᑦᑕᕐᒪᑕ ᑕᒪᓐᓇᓗ ᖃᖓᑕᓲᒥ ᐊᑐᕐᓂᕐᒧᑦ ᐊᒻᒪ ᐋᓐᓂᐊᕕᖕᒦᓐᓂᕐᒧᑦ ᑮᓇᐅᔭᑲᓪᓚᖕᓂ ᐊᑐᕈᑎᐅᓕᖅᐸᒃᖢᓂ. (ᐊᔾᔨᙳᐊᖁᑎᒋᔭᐅᔪᖅ)

By ᔨᒻ ᐱᐊᓪ

For an English version of this story, see Expand use of anti-RSV agent in Nunavut, thousands of petitioners say

ᐅᑯᐊ ᓘᒃᑖᖅ ᐋᓇ ᐸᓄᕐᔨ ᐊᒻᒪ ᐃᓕᓴᐃᔨᐅᖃᑎᖏ ᑐᕌᓐᑐ ᔫᓂᕘᓯᑎᐅᑉ ᐋᓐᓂᐊᖃᖅᑕᐃᓕᓂᕐᒧᑦ ᐃᓕᓐᓂᐊᕐᕕᖓᓂ ᐃᓕᓐᓂᐊᖃᑎᒌᖕᓂᑯᑦ 1989-ᒥ ᓯᕗᓪᓕᖅᐹᒥ ᑕᒪᑐᒥᖓ ᓴᖅᑭᑎᑦᑎᓚᐅᕐᓯᒪᔭᖓ ᐅᕘᓇ change.org ᓯᑎᐱᕆᐅᑉ ᓄᙳᐊᓂᒃ, ᐊᒻᒪᓗ 1,000-ᖏᓐᓃᑦᑐᓂᒃ ᐊᑎᓕᐅᖅᑕᐅᓇᔭᖁᓪᓗᒍ ᐊᖏᖃᑕᐅᔪᓂᒃ.

ᑭᓯᐊᓂᓕ ᐅᓇ ᑐᓴᒐᒃᓴᓕᐊᖅ ᑎᑎᕋᖅᑕᐅᑕᐃᓐᓇᖅᑎᓪᓗᒍ, 23,322-ᓂ ᐊᑎᕐᓂ ᑲᑎᑦᑎᓯᒪᓕᓚᐅᕐᑐᑦ—ᐊᒻᒪ ᒫᓐᓇ ᑎᑭᐅᑎᔪᒪᓕᖅᖢᑎᒃ 25,000-ᓄ ᐊᑎᓕᐅᕐᓯᒪᔪᓂ.

ᖃᐅᔨᔭᐅᑎᑦᑎᔾᔪᑎᒋᓇᓱᒃᑕᖓ ᐅᖃᕐᓯᒪᔪᖅ ᐃᒪᓐᓇ ᓄᓇᕗᑦ ᒐᕙᒪᖓᑦ ᐊᒥᓱᓂᒃ ᐃᓅᔪᓐᓃᕋᔭᖅᑐᓂᒃ ᓴᐳᔾᔨᓯᒪᒐᔭᕐᓂᖏᓐᓂᒃ ᐊᒻᒪᓗ ᐋᓐᓂᐊᕐᕕᓕᐊᕆᐊᖃᕈᓐᓃᖅᐹᓪᓕᕐᓗᑎᒃ ᓄᑕᕋᓛᑦ ᐊᑐᓕᖅᑎᑦᑎᒃᑲᓐᓂᕈᑎ ᐋᓐᓂᐊᖅᑖᖅᑕᐃᓕᒍᑎᒥ ᑕᐃᔭᐅᔪᒥᓐ palivizumab ᑕᒪᐃᓐᓄᓕᒫᖅ ᓄᑕᕋᓛᓄᑦ ᑕᖅᑭᖃᖅᑐᓂᒃ 6 ᑐᖔᓂᒃ.

Palivizumab ᐋᓐᓂᐊᖅᑖᖅᑕᐃᓕᒍᑎᐅᔪᖅ, ᑲᐱᔭᐅᔾᔪᑎᐅᙱᑲᓗᐊᖅᖢᓂ, ᐊᒻᒪᓗ ᓂᐅᕐᕈᑎᐅᓇᓱᖕᓂᖓᒍᑦ ᐊᑎᖃᖅᑎᑕᐅᓪᓗᓂ Synagis-ᒥᑦ.

ᓇᓗᓇᐃᖅᑕᐅᓯᒪᓪᓚᕆᒃᑐᖅ ᓄᑕᕋᓛᓂ ᐳᕙᖏᑦᑎᒍᑦ ᐋᓐᓂᐊᕐᓇᙱᑦᑐᖃᕐᓂᕐᓴᐅᔭᓐᓂᖓᓂᒃ ᐱᒋᐊᕈᑎᓕᖕᓂᒃ ᐆᒧᙵᑦ RSV, ᓇᐃᓈᕈᑎᒋᔭᐅᔪᖅ ᐆᒧᖓ “respiratory syncytial virus,” ᑖᓐᓇᓕ ᐊᓪᓕᕐᓂ ᐳᕙᖕᓄᐊᔭᖢᓂ, ᐊᒻᒪ ᐋᓐᓂᐊᖅᑖᕈᑎᐅᓕᖅᐸᒃᖢᑎ ᖁᐊᕐᓵᕐᒃᓇᒻᒪᕆᒃᑐᒥᑦ ᑕᐃᔭᐅᔪᒥ bronchiolitis-ᒥ.

ᑭᓯᐊᓂᓕ ᓘᒃᑖᖅ ᒪᐃᑯᓪ ᐹᑐᓴᓐ, ᐊᖓᔪᖅᑳᖅ ᐋᓐᓂᐊᖅᑐᓕᕆᓂᕐᒥ ᓄᓇᕗᒥᑦ, ᐅᖃᓚᐅᕐᑐᖅ ᓄᓇᑦᓯᐊᕐᒥ ᐱᕙᓪᓕᐊᔪᓄᑦ ᐊᐱᖅᓱᖅᑕᐅᑎᓪᓗᒍ ᐅᑯᐊ ᓄᓇᕗᑦ ᒐᕙᒪᒃᑯᑦ ᑐᓂᓯᕙᖕᓂᖏᓐᓂᒃ palivizumab-ᒥ 11 ᐳᓴᙱᓐᓂᒃ 12 ᐳᓴᓐᑎᒧᑦ ᓄᑕᕋᓄᑦ ᐊᕐᕌᒍᖃᖅᑐᓄᑦ 2 ᑐᖔᓂ.

“ᐊᑐᖃᑦᑕᕐᓂᕐᓴᐅᒐᑦᑎᒍᑦ ᒪᑯᓄᖓ ᓄᑕᕋᕐᓄᑦ ᐅᓗᕆᐊᓇᖅᑐᒦᓐᓂᕐᓴᓄᑦ ᐋᓐᓂᐊᖅᑖᓗᐊᕋᔭᖅᑐᓂᒃ RSV-ᒧᑦ, ᐊᒻᒪᓗ ᒪᑯᓄᖓ ᐃᑲᔪᖅᑐᐃᕙᒃᑐᓄᑦ ᓄᓇᕐᔪᐊᒥ ᑐᓂᔭᖏᓐᓄᑦ palivizumab-ᒥᑦ,” ᐅᖃᖅᑐᖅ.

ᐅᑯᐊ ᐃᓚᖃᖅᑐᑦ ᓄᑕᕌᓚᓄ ᐃᓄᕐᖢᑎᒃ ᐃᓅᔪᓄᑦ, ᐱᓇᓱᐊᕈᓯᓕᖕᓂ 35 ᑐᖔᓃᑦᑐᓂ ᓇᔾᔨᐊᕆᔭᐅᓂᖏᑦᑎᒍᑦ, ᐅᕝᕙᓘᓐᓃᑦ ᓄᑕᕋᕐᓄᑦ ᐳᕙᖏᑦᑎᒍᑦ ᐋᓐᓂᐊᖃᐃᓐᓇᖅᑐᓄᑦ ᐅᕝᕙᓘᓐᓃᑦ ᐆᒻᒪᑎᒃᑯᑦ ᐋᓐᓂᐊᓕᖕᓄᑦ.

ᐸᓄᕐᔨ, ᐃᓕᓴᐃᔨᐅᖃᑕᐅᔪᖅ ᓱᕈᓯᓕᕆᓂᕐᒥ ᑐᕌᓐᑐ ᔫᓂᕘᓯᑎᒥ ᐃᓅᓕᓴᐅᑎᓕᕆᓂᕐᒧᑦ, ᐃᓕᓐᓂᐊᕈᑎᒃᓴᓂᒃ ᑎᑎᕋᐅᓯᖃᐅᓯᒪᓕᕐᑐᖅ ᐊᕐᕌᒍᓂᒃ 15-ᓂ ᒪᑯᓂᖓ ᓴᖅᑭᔮᖏᓐᓇᐅᔭᕐᓂᐅᔪᓂᒃ ᐊᒻᒪ ᐊᑭᖃᑎᒋᓂᖓᓂᒃ RSV ᐅᑭᐅᕐᑕᖅᑐᕐᒥᑦ.

ᖃᐅᔨᓴᕈᑎᐅᔪᑎᒍᓪᓕ, ᑖᓐᓇ ᓈᒻᒪᒃᓴᖅᓯᒪᙱᓪᓚᕆᒃᑐᖅ ᒫᓐᓇ ᓄᓇᕗᒥᑦ ᐊᑐᐊᒐᐅᔪᒥᒃ ᐊᒻᒪᓗ ᐅᖃᖅᖢᓂ ᑕᒪᕐᒥᓕᒫᖅ ᓄᓇᕗᒥᑦ ᓄᑕᕋᓛᑦ ᑖᔅᓱᒥᖓ ᐋᓐᓂᐊᖅᑖᖅᑕᐃᓕᒍᑎᒥ ᐱᔭᕆᐊᖃᕐᒪᑕ.

ᓘᒃᑖᖅ ᐋᓇ ᐸᓄᕐᔨ, ᐃᓕᓐᓂᐊᖅᑎᑦᑎᔨᒻᒪᕆᐅᖃᑕᐅᔪᖅ ᓱᕈᓯᓕᕆᓂᕐᒥ ᐅᕙᓂ ᑐᕌᓐᑐ ᔫᓂᕘᓯᑎᐅᑉ ᐃᓅᓕᓴᐅᑎᓕᕆᓂᕐᒧᑦ, ᐅᖃᓚᐅᕐᑐᖅ ᖃᐅᔨᓴᑲᑕᓚᐅᖅᖢᓂ ᐃᓄᐃᑦ ᓄᑕᕋᓛᖏᓐᓂᒃ ᑲᐱᓯᑲᑕᒃᑯᑎᒃ ᐋᓐᓂᐊᖅᑖᖅᑕᐃᓕᒍᑎᒥ ᑕᐃᔭᐅᔪᒥᒃ palivizumab ᐃᑲᔫᑎᒻᒪᕆᐅᓇᔭᕐᓂᖓᓂᒃ ᐃᓅᓯᕐᓂᒃ ᐊᒻᒪ ᑮᓇᐅᔭᑎᒍᑦ. (ᐊᔾᔨᙳᐊᖁᑎᒋᔭᐅᔪᖅ)

ᓄᓇᕗᒥᑦ ᐊᑭᒋᕙᒃᑕᖏᓐᓄᑦ ᑕᐃᒪᓐᓇ ᐊᑑᑎᖃᒻᒪᕆᒃᑐᖅ

ᐅᖃᓚᐅᕐᑐᖅ ᖃᐅᔨᓴᖅᑕᖏᑦᑎᒍᑦ ᐅᓇ RSV ᐋᓐᓂᐊᕆᔭᐅᕙᒃᑐᖅ ᐱᑕᖃᐃᓐᓇᔭᓐᓂᖓᓂ ᐅᓄᕈᓘᔭᖅᑐᓄᐊᕈᓐᓇᕐᓂᖓᓂᒡᓗ ᐊᒻᒪᓗ ᓴᖅᑭᑎᑦᑎᒍᑎᐅᓕᔭᖢᓂ ᐅᓄᕈᓘᔭᖅᑐᓂᒃ ᖃᖓᑕᓲᒃᑰᖅᑎᑦᑎᒍᑎᓂᒃ ᐊᒻᒪ ᐋᓐᓂᐊᕕᖕᒦᒍᑎᓂᒃ ᐅᑯᓄᖓ ᓄᓇᕗᒥᑦ ᐋᓐᓂᐊᖃᕐᓇᙱᑦᑐᓕᕆᔨᓄᑦ.

ᐋᓐᓂᐊᖅᑖᖅᑕᐃᓕᒍᑎ ᐊᑭᑐᔪᐊᓘᖕᒪᓐ: ᒫᓂ $5,600 ᐊᑕᐅᓯᕐᒧᑦ ᐃᓅᓕᓴᕈᑎᒧᓐ. ᑭᓯᐊᓂᓕ ᑕᐃᒪᓐᓇ ᐊᑭᖃᕋᓗᐊᖅᑎᓪᓗᒍ, ᐸᓄᕐᔨ ᐊᒻᒪ ᐊᒥᓱᑦ ᐅᒃᐱᕈᓱᒃᑐᑦ ᑖᓐᓇ ᓲᕐᓗ ᐊᑭᒃᖠᒋᐊᕐᓯᒪᔪᖅ.

ᑕᐃᒪᐃᔾᔪᑎᓕᒡᓕ ᓄᓇᕗᒥ ᐋᓐᓂᐊᖅᑖᕐᓴᕋᐃᖃᑦᑕᕐᒪᑕ ᐊᒻᒪᓗ ᑐᐊᕕᕐᓇᖅᑐᒃᑯᑦ ᐊᐅᓪᓚᖅᑎᑦᑎᕙᖕᓂᖅ ᐊᑲᐅᓛᖑᕙᒃᖢᓂ, ᑭᐅᓘᑎᖃᖅᑐᑦ.

“ᐊᒥᓱᓂ ᐊᑭᓕᐅᑎᒍᑎᐅᓇᔭᖅᑐᓂᒃ ᖃᐅᔨᓴᕐᓯᒪᔪᒍᑦ ᓴᖅᑭᑎᑦᑎᓯᒪᔪᓂᒃ ᐅᑭᐅᕐᑕᖅᑐᒥ ᐊᒥᓲᓂᕐᓴᓂᒃ ᑐᓂᓯᒍᑦᑕ palivizumab-ᒥ, ᑮᓇᐅᔭᓂ ᐊᑐᙱᓐᓂᕐᓴᐅᓇᔭᕐᓂᕐᒥᓐ,” ᐅᖃᓚᐅᕐᑐᖅ ᐊᐱᖅᓱᖅᑕᐅᑎᓪᓗᒍ.

ᐊᑭᖏᑦᑎᒍᑦ ᖃᐅᔨᓴᕐᓂᒃᑯᓐ, ᑎᑎᕋᖅᑕᐅᓂᑯᓂᒃ 2013-ᒥ, ᖃᐅᔨᒍᑎᐅᓚᐅᕐᓯᒪᔪᖅ ᐊᒥᓱᒻᒪᕆᖕᓂᒃ ᐳᕙᖏᑦᑎᒍᑦ ᐋᓐᓂᐊᖃᖅᑐᓂᒃ ᕿᑎᕐᒥᐅᑦ ᓄᑕᕋᓛᖏᓐᓂᒃ: ᐋᖅᑭᒃᑕᐅᓯᒪᓪᓗᓂ 389 ᐅᕙᙵᑦ 1,000-ᓂ.

ᖃᐅᔨᓴᖅᑎᓪᓗᒋᑦ, ᑖᓐᓇᓗ ᐱᓕᕆᐊᖑᓂᑰᓪᓗᓂ ᔭᓄᐊᕆ 1, 2009-ᒥ ᔫᓂ 30, 2010-ᒧᑦ, ᖃᐅᔨᓕᓚᐅᕐᑐᑦ ᐊᑭᓕᐅᑕᐅᓂᐅᕙᒃᑐᑦ ᐋᓐᓂᐊᕐᕕᖕᒦᓐᓂᕐᒧᑦ ᑖᔅᓱᒥᖓ ᐋᓐᓂᐊᖃᕐᓂᕐᒧᑦ ᒪᐅᖓ ᑎᑭᓚᐅᕐᓯᒪᓂᖏᓐᓂᒃ $57,535-ᒧᑦ.

ᕿᑭᖅᑕᓂᓪᓕ, ᐳᕙᒃᑯᑦ ᐋᓐᓂᐊᖅᑖᖃᑦᑕᖅᑐᑦ ᓄᑕᕋᓛᓂᒃ ᐃᒪᐃᓕᖓᓚᐅᕐᐳᑐᖅ 2002 ᐅᕙᙵᑦ 1,000-ᓂ ᐃᓅᓵᕐᓂᑯᓂᒃ ᐊᒻᒪ ᑭᕙᓪᓕᕐᒥ, 230 ᐅᕙᙵᑦ 1,000-ᓂ ᐃᓅᓵᖅᑐᓂᒃ.

ᐅᓇ ᑐᑭᖃᖅᑐᖅ ᓄᓇᕗᑦ ᒐᕙᒪᒃᑯᑦ ᐊᑐᕐᓯᒪᓂᖏᓐᓂᒃ $5.9 ᒥᓕᐊᓐᑖᓚᓂ ᐋᓐᓂᐊᕐᔪᐊᖅᑐᑯᓗᖕᓄᑦ ᕿᑭᖅᑕᓂ ᓄᓇᑕᕌᓛᓄᑦ ᐊᒻᒪ ᒫᓂᐸᓗᒃ $5.7 ᒥᓕᐊᓐᑖᓚᓂ ᑭᕙᓪᓕᕐᒥ ᓄᑕᕋᓛᓄᑦ ᐋᓐᓂᐊᕐᑐᓄᑦ ᑕᒪᓐᓇ ᑕᐃᒪᐃᓕᖓᓚᐅᕐᑐᖅ ᖃᐅᔨᓴᕐᓂᖏᓐᓂᒃ.

ᑭᓯᐊᓂᓕ, ᐃᒪᐃᓕᖓᓚᐅᕐᑐᖅ, ᑭᕙᓪᓕᖅ ᖁᑦᑎᖕᓂᕐᐹᖑᓚᐅᕐᑐᖅ ᐳᕙᖏᑦᑎᒍᑦ ᐋᓐᓂᐊᖃᖅᑐᓂᒃ ᐋᓐᓂᐊᕕᖕᒦᑎᑦᑎᓂᕐᒧᑦ: $63,686.

“ᐃᓄᖕᓄᓪᓕ, ᑮᓇᐅᔭᓂᒃ ᐊᑐᓗᐊᕐᓇᙱᓐᓂᕐᓴᐅᔪᖅ, ᓲᖃᐃᒻᒪ ᐳᕙᖏᑦᑎᒍᑦ ᐋᓐᓂᐊᖅᑖᖅᐸᒃᑐᑦ ᖁᑦᑎᒃᑐᒦᖃᑦᑕᖕᓂᖓᓄᑦ,” ᐅᖃᖅᑐᖅ.

ᐊᖓᔪᖅᑳᕆᔭᐅᔪᖅ ᐋᓐᑎᐅᕆᐅᒥ ᐋᓐᓂᐊᓯᐅᕐᑎᓄᑦ ᐃᑲᔪᖅᑐᐃᕗᖅ ᐊᑎᓕᐅᕐᕕᐅᑎᑕᒥᑦ

“ᐃᓄᐃᑦ ᓄᑕᕋᓛᖏᑦ ᖁᓖᓱᖅᖢᑎᒃ ᐋᓐᓂᐊᕕᖕᒥᑦ ᑲᒪᒋᔭᐅᒋᐊᖃᕐᓂᕐᓴᐅᕙᖕᒪᑕ ᐳᕙᖏᑦᑎᒍᑦ ᐋᓐᓂᐊᖃᕐᓂᕐᒧ ᐅᑯᓇᙵᓪᓕ “ᐅᓗᕆᐊᓇᖅᑐᒦᑦᑐᓂᒃ” ᓄᑕᕋᓛᓂᒃ ᐊᒻᒪᓗ ᐋᓐᓂᐊᕆᔭᐅᔪᖅ ᐱᓂᕐᓴᐅᒻᒪᕆᒃᖢᓂ ᐃᒃᐱᖕᓇᕐᓂᖓᒍᑦ. ᑕᒪᓐᓇ ᓈᒻᒪᙱᓕᐅᕈᑎᐅᒻᒪᕆᒃᑲᓗᐊᖅᑎᓪᓗᒍ, ᐃᓄᐃᑦ ᓄᑕᕋᓛᖏᑦ ᓄᓇᕗᒥᑦ ᐋᓐᓂᐊᖅᑖᖅᑕᐃᓕᒍᑎᑖᖅᐸᙱᑦᑐᑦ,” ᒑᓐᑎ ᑎᑎᕋᓚᐅᕐᑐᖅ ᑐᓐᓂᖁᑎᖏᓐᓂᒃ.

ᐅᓇᑦᑕᐅ ᖃᓄᐃᓕᖓᓂᐅᔪᖅ ᐊᔪᕈᓐᓃᕐᓯᒪᒻᒪᕆᒃᑐᓄᑦ ᓇᓗᓇᐃᖅᑕᐅᓯᒪᔪᑦ ᐅᕙᓂ ᐅᐊᓇᖅᐸᓯᖕᒥᑦ ᐃᓕᓐᓂᐊᕐᕕᖕᒥᑦ ᐋᓐᓂᐊᖃᖅᑕᐃᓕᓂᕐᒧᑦ, ᑲᓇᑕᒥ ᐋᓐᓂᐊᖃᕐᓇᙱᑦᑐᓕᕆᔨᒃᑯᑦ ᑲᑐᔾᔨᖃᑎᒌᖏᓐᓂᒃ ᐊᒻᒪᓗ ᑲᓇᑕᒥ ᐋᓐᓂᐊᖃᖅᑐᓕᕆᓂᕐᒧᑦ ᖃᐅᔨᓴᕕᖕᒥᑦ ᓄᓇᖃᖅᑳᖅᑐᓄᑦ.

ᑭᓯᐊᓂᓕ ᖃᓄᐃᙱᑦᑐᑦ ᓄᑕᕋᓛᑦ ᓄᓇᕗᒥᑦ ᐃᓱᓕᑦᑎᓪᓗᑎᒃ ᐃᕐᓂᐊᕆᔭᐅᔪᑦ ᑖᔅᓱᒥᖓ ᐋᓐᓂᐊᖅᑖᖅᑕᐃᓕᒍᑎᒥ ᐱᑎᑕᐅᕙᙱᑦᑐᑦ—ᒪᑯᓇᙶᕋᓗᐊᕈᑎᒃ ᖁᐊᕐᓵᕐᓇᖅᑐᒦᑐᓂᒃ ᓄᓇᓕᖕᓂᑦ ᐃᖃᓗᐃᑦ ᐊᓯᐊᓂᑦ ᐊᒻᒪ ᐋᓐᓂᐊᑐᖃᐅᕐᓂᕐᓴᐅᕙᒃᖢᑎᒃ ᐳᕙᒃᑯᑦ ᐋᓐᓂᐊᕈᑎᒥᓐ.

ᐸᓄᕐᔨ ᐅᖃᖅᑐᖅ ᑕᐃᒪᓐᓇ ᑕᒻᒪᕐᓯᒪᓂᖏᓐᓂᒃ ᐱᓕᕆᐊᖃᕐᓂᕐᒥᓐ.

“ᐱᓕᕆᓯᒪᒻᒪᕆᒃᑲᒪ ᐊᒃᓱᕈᖅᖢᖓ. ᑕᑯᑎᓯᒪᓪᓗᒋᓪᓗ ᓇᓗᓇᐃᔭᖅᐸᓪᓕᐊᔭᒃᑲ ᑭᒃᑯᑐᐃᓐᓇᕐᓄᑦ. ᑭᐅᕈᓕᓐ ᐸᓇᑦ, ᔭᐃᓐ ᕕᐊᐹᑦ, ᑕᑯᓯᒪᖕᒪᑕ ᑎᑎᕋᕐᓯᒪᔭᓐᓂᒃ ᐊᒻᒪ ᐅᖃᕐᓯᒪᓪᓗᑎᒃ ᐅᒃᐱᕐᓇᕐᓂᖏᓐᓂᒃ,” ᐅᖃᖅᑐᖅ.

ᓄᓇᕕᒃᒥ ᑲᐱᓯᓲᑦ ᓄᑕᕋᓛᓕᒫᓂᒃ

ᖃᐅᔨᑎᑦᑎᒋᐊᓚᐅᖅᖢᓂᓗ, ᓄᓇᕗᑎᑑᙱᑦᑐᖅ, ᐋᓐᓂᐊᖃᕐᓇᙱᑦᑐᓕᕆᔨᐅᔪᑦ ᓄᓇᕕᒃᒥ ᑐᓂᓯᓯᒪᕗᑦ palivizumab-ᒥᑦ ᑕᒪᐃᓐᓄᑦ ᓄᑕᕋᓛᓄᑦ ᐊᕐᕌᒎᓕᖅᑐᓂᒃ ᐱᖓᓱᓂᒃ.

ᓄᓇᕗᑦ ᒪᓕᒐᓕᕆᕕᒡᔪᐊᖓᓂ ᐅᒃᑑᐱᕆ 18-ᖑᑎᓪᓗᒍ, ᐋᓐᓂᐊᖃᕐᓇᙱᑦᑐᓕᕆᔨᒃᑯᑦ ᒥᓂᔅᑕᖓᓐ ᔪᐊᔾ ᕼᐃᒃᔅ ᐅᖃᓚᐅᕐᑐᖅ ᑭᐅᓪᓗᓂ ᐊᐱᖅᑯᑎᓂᒃ ᐅᕙᙵᑦ ᐃᖃᓗᐃᑦ-ᓂᐊᖁᙴᒧᑦ ᒪᓕᒐᓕᐅᕐᑎᒥᑦ ᐹᑦ ᐊᕐᓇᒃᑲᒃ, ᐅᑯᐊ ᓄᓇᕗᑦ ᒐᕙᒪᒃᑯᑦ ᕿᒥᕐᕈᐊᑦᑎᐊᖁᓪᓗᒋᑦ ᓄᓇᕕᒃ ᖃᓄᐃᓕᐅᕈᓯᖏᓐᓂᒃ.

“ᖃᐅᔨᒪᓇᓱᒃᐸᓪᓕᐊᔭᕗᑦ ᑕᐃᓐᓇ ᐱᓕᕆᐊᖑᔪᖅ,” ᐅᖃᖅᑐᖅ ᕼᐃᒃᔅ.

ᐊᕐᓇᑲᒃ ᐅᖃᓚᐅᕐᑐᖅ ᐅᓇ RSV (ᐳᕙᖕᒧᑦ ᐋᓐᓂᐊᓕᕈᑎ) ᐊᒃᓱᐊᓗᒃ ᐊᒃᑐᐃᓂᖃᖃᑦᑕᕐᓂᖓᓂᒃ ᐃᓚᒌᓄᑦ.

“ᖃᖓᑦᑎᐊᖑᓚᐅᕐᑐᖅ, ᖃᐅᔨᒪᔭᒃᑲ ᓄᑕᕋᓛᖓ ᐋᓐᓂᐊᕕᓕᖕᒧᑦ ᐊᐅᓪᓚᖅᑎᑕᐅᔭᕆᐊᖃᓕᓚᐅᕐᑐᖅ RSV-ᒧᑦ ᐊᒻᒪᓗ ᐊᒃᑐᐃᓂᖃᒻᒪᕆᒃᖢᓂ ᐃᓚᒌᓄᑦ, ᐱᓗᐊᖅᑐᒥ ᑖᓐᓇ ᓄᑕᕋᓛᖑᓗᐊᖅᑎᓪᓗᒍ.

ᑭᓯᐊᓂᓕ ᕼᐃᒃᔅ ᓴᐳᔾᔨᓚᐅᕐᑐᖅ ᓄᓇᕗᑦ ᒐᕙᒪᒃᑯᑦ ᒫᓐᓇ ᐱᓕᕆᔾᔪᓯᐊᓂᒃ ᐊᒻᒪ ᐃᒪᐃᙱᓐᓂᕋᐃᓪᓗᓂ ᒐᕙᒪᖓᑦ ᑮᓇᐅᔭᓂᒃ ᐊᑐᓗᐊᖅᑕᐃᓕᒪᓂᕐᒧᑦ ᐃᓄᖅᑐᓂᒃ ᑭᓯᐊᓂ ᑖᔅᓱᒥᖓ ᐱᑎᑦᑎᕙᖕᓂᖏᓐᓂᒃ.

“ᐅᓇ ᒪᓕᒐᓕᕆᓂᒃᑯᑦ ᐅᕝᕙᓘᓐᓃᑦ ᐊᑐᐊᒐᑎᒍᑦ ᐃᓱᒪᓕᐅᕆᔭᐅᓯᒪᙱᒻᒪᑦ ᐊᑭᖓ. ᒪᓕᒃᓯᒪᖕᒪᑦ ᐱᐅᓂᖅᐹᒃᑯᑦ ᐋᓐᓂᐊᖅᑐᓕᕆᓂᕐᒥᑦ ᐱᓕᕆᓂᒃᑯᑦ,” ᕼᐃᒃᔅ ᐅᖃᖅᑐᖅ.

ᐹᑐᓴᓐ ᐅᖃᒃᑲᓐᓂᕐᖢᓂ ᓄᓇᕕᒃᒥᑦ ᑲᔪᓯᓚᐅᕐᓯᒪᓂᖏᓐᓂᒃ ᐊᕐᕌᒍᑦ ᐱᖓᓱᑦ ᓯᕗᓂᐊᓂ ᑕᒪᒃᑯᐊ ᐱᒋᐊᕐᕕᖃᖅᖢᑎᒃ ᓄᑕᕋᓛᓂᑦ ᑕᖅᑭᖃᖅᑐᓂᒃ 6 ᑐᖔᓂᑦ.

“ᐅᑕᖅᑭᒐᑦᑕ ᓱᓕ ᑕᒪᑐᒪ ᓇᐃᓴᐅᑎᖏᓐᓂᒃ, ᐊᒻᒪᓗ ᖃᐅᔨᑦᑎᐊᕈᑦᑕ ᑮᓇᐅᔭᓂ ᐊᑐᙱᑉᐹᓪᓗᕐᓂᖓᓂᒃ ᐊᑐᖅᑎᑦᑎᓗᓂ palivizumab-ᒥ, ᑕᐃᒪᓕ ᑕᒪᓐᓇ ᐊᑐᓕᖅᑎᑲᐅᖅᑐᕋᔭᖅᑕᕗᑦ,” ᐹᑐᓴᓐ ᐅᖃᖅᑐᖅ.

ᑭᓯᐊᓂᓕ ᐃᓱᒪᒋᔭᖓᒍᑦ, ᓱᓕ ᐱᑕᖃᙱᓗᐊᕐᒪᓐ ᓇᓗᓇᐃᒃᑯᑎᓪᓚᕆᐅᓇᔭᖅᑐᓂᒃ ᐊᑐᖅᑕᐅᑎᑦᑎᓕᕐᓂᕐᒥ ᓄᓇᕗᒥᑦ.

“ᒪᕐᕉᖕᒪᑎ ᐊᖏᖃᑎᒋᙱᑕᒃᑲ ᐊᑎᓕᐅᖅᑎᑦᑎᓇᓱᖕᓂᕐᒥ ᐊᒻᒪ ᐱᖃᑎᖓᓕ ᓴᖅᑭᑎᑦᑎᒍᑎᐅᔪᖅ ᑕᒪᓐᓇ ᐱᔭᕇᖅᑕᐅᓯᒫᓂᖕᓂᖓᓂᒃ, ᐅᕝᕙᓘᓐᓃᑦ ᖃᐅᔨᓴᖅᑐᓕᕆᓂᒃᑯᑦ ᑕᒪᑐᒧᖓ ᓇᓗᓇᐃᔭᕈᑎᑕᖃᕆᐊᒃᓴᖓᓂᒃ. ᐊᒥᓱᓂᒃ ᐃᓄᖕᓂ ᓱᓕ ᐊᐱᖅᑯᑎᒃᓴᖃᖅᑐᖃᐅᕐᒪᓐ,” ᐅᖃᖅᑐᖅ.

ᖃᓄᐃᓕᐅᕈᓘᔭᕈᑎᐅᔪᖅ ᐊᑐᖅᑕᐅᕙᖕᓂᖓ palivizumab ᓄᓇᕗᒥᑦ ᖃᖓᑲᓪᓛᓗᖕᓂᙶᖅᓯᒪᕗᖅ.

2008-ᒥ, ᓄᓇᕗᑦ ᒐᕙᒪᒃᑯᑦ ᐊᖏᙱᑦᑎᐊᒻᒪᕆᓚᐅᕐᓯᒪᖕᒪᑕ ᐃᓚᐅᔭᕆᐊᒃᓴᕐᓘᓐᓃᑦ ᐸᓄᕐᔨᐅᑉ ᖃᐅᔨᓴᕈᑎᖏᓐᓂᒃ ᐆᒥᖓ RSV, ᐅᑯᐊᓘᓐᓃᑦ ᐱᓕᕆᔨᒻᒪᕆᐅᔪᑦ ᑲᓛᖡᑦ ᓄᓇᖓᓂᒃ, ᓄᓇᕕᒃᒥᑦ ᐊᒻᒪ ᓄᓇᑦᓯᐊᕐᒥᑦ ᐃᓚᐅᔪᒪᑎᓪᓗᒋᑦ.

Share This Story

(0) Comments

Join the Conversation

Your email address will not be published. Required fields are marked *

*


Protected with IP Blacklist CloudIP Blacklist Cloud